Next generation antibody treatments for ovarian cancer

IGEM Therapeutics Ltd旨在开发新的平台技术，以创造具有增强抗肿瘤活性的治疗性IgE分子。IgE的Fc区已被设计为引入额外的功能，以改善抗肿瘤反应，特别是用于治疗实体肿瘤。该项目的直接产出将是一种具有优越抗癌活性的靶向fr的变异型IgE抗体。预计一组目前靶向治疗效果不佳的卵巢癌患者将成为这种治疗方式的早期受益者。更一般地说，该项目解决了为实体瘤专利提供更好结果的迫切需要。IGEM的目标是在全球免疫肿瘤学市场取得领先地位，预计到2025年将达到280亿美元。

IGEM Therapeutics Ltd aims to develop new platform technologies for creating therapeutic IgE molecules with enhanced anti-tumour activities. The Fc region of IgE has been engineered to introduce additional functionality with a view to improving anti-tumour responses, in particular for treatment of solid tumours. An immediate output of the project will be a FRa-targeting variant IgE antibody with superior anti-cancer activity. It is expected that a cohort of ovarian cancer patients who are presently poorly served by targeted therapies will be early beneficiaries of such a modality. More generally, the project addresses the pressing need to provide better outcomes for patents with solid tumours. IGEM aims to attain a leading position in the global immune-oncology market which is forecast to reach $28 billion by 2025\.